Accepted Manuscript



A 90-day OECD TG 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects of the aerosol from the carbon heated tobacco product version 1.2 (CHTP1.2) compared with cigarette smoke. I. Inhalation exposure, clinical pathology and histopathology

Blaine W. Phillips, Walter K. Schlage, Bjoern Titz, Ulrike Kogel, Davide Sciuscio, Florian Martin, Patrice Leroy, Gregory Vuillaume, Subash Krishnan, Tom Lee, Emilija Veljkovic, Ashraf Elamin, Celine Merg, Nikolai V. Ivanov, Manuel C. Peitsch, Julia Hoeng, Patrick Vanscheeuwijck

PII: S0278-6915(18)30217-5

DOI: 10.1016/j.fct.2018.04.015

Reference: FCT 9704

To appear in: *Food and Chemical Toxicology*

Received Date: 3 January 2018

Revised Date: 28 March 2018

Accepted Date: 7 April 2018

Please cite this article as: Phillips, B.W., Schlage, W.K., Titz, B., Kogel, U., Sciuscio, D., Martin, F., Leroy, P., Vuillaume, G., Krishnan, S., Lee, T., Veljkovic, E., Elamin, A., Merg, C., Ivanov, N.V., Peitsch, M.C., Hoeng, J., Vanscheeuwijck, P., A 90-day OECD TG 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects of the aerosol from the carbon heated tobacco product version 1.2 (CHTP1.2) compared with cigarette smoke. I. Inhalation exposure, clinical pathology and histopathology, *Food and Chemical Toxicology* (2018), doi: 10.1016/j.fct.2018.04.015.

A 90-day OECD TG 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects of the aerosol from the carbon heated tobacco product version 1.2 (CHTP1.2) compared with cigarette smoke. I. Inhalation exposure, clinical pathology and histopathology

Blaine Phillips[c] , Walter Schlage[b], Bjoern Titz[a,*], Ulrike Kogel[a,*], Davide Sciuscio[a], Florian Martin[a], Patrice Leroy[a], Gregory Vuillaume[a], Subash Krishnan [c], Tom Lee [c], Emilija Veljkovic [c], Ashraf Elamin[a], Celine Merg[a], Nikolai V. Ivanov[a], Manuel C. Peitsch[a], Julia Hoeng[a] , Patrick Vanscheeuwijck[a]

[a] Philip Morris International Research and Development, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland (part of Philip Morris International group of companies)

[b] Biology consultant, Max-Baermann-Str. 21, 51429 Bergisch Gladbach, Germany

[c] Philip Morris International Research Laboratories, 50 Science Park Road, Singapore, Singapore (part of Philip Morris International group of companies)

Corresponding author:

Patrick Vanscheeuwijck, Ph.D.

E-mail: Patrick.Vanscheeuwijck@pmi.com

Tel: +41 (58) 242 2511